Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)

a neuropsychiatric syndrome and autoimmune neuropsychiatry technology, applied in the field of pandas, can solve the problems of inconvenient and accurate diagnosis, difficulty in agreeing on standard nomenclature for such conditions, and children that used to be comforted by hugs are now inconsolable, so as to achieve convenient and accurate diagnosis, reliably diagnose pans and/or pandas, and effective and timely

Inactive Publication Date: 2016-06-09
THE BOARD OF RGT UNIV OF OKLAHOMA +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The proposed method enables reliable diagnosis of PANS and PANDAS, facilitating more effective and timely treatment, potentially improving patient outcomes and reducing the economic burden by moving treatments out of the experimental phase and into insurance coverage.

Problems solved by technology

A child that used to be comforted by a hug is now inconsolable.
Thus, parents turning to the medical community are often at a loss since currently there are no clinical methods or tests to provide or confirm a diagnosis.
This is why there is significant difficulty in making a PANDAS / PANS diagnosis based upon symptoms alone; indeed, there is even difficulty in agreeing upon standard nomenclature for such conditions.
In some cases, however, tic conditions have actually worsened.
Such treatments can only be used for short time periods due to possible serious long-term complications.
And even where improvements are observed, symptoms often return after termination of treatment—sometimes to even worse levels.
And such treatments can be very expensive—$50,000 or higher in some cases.
Moreover, significant side effects—up to, and including, death—can result from such treatments.
The lack of clinical methods or tests to provide or confirm a PANS or PANDAS diagnosis presents significant obstacles to providing effective therapies to children suffering from PANS or PANDAS and their parents seeking such therapies.
After all, such current treatments regimes can be uncertain in outcome, expose the patient to significant side effects as well as long term, painful, and difficult procedures, and expose the parents to very high economic costs.
Indeed, this need has been unmet since the first identification of PANDAS / PANS in the 1980s and remains unmet today.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)
  • Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)
  • Diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (pandas)

Examples

Experimental program
Comparison scheme
Effect test

example 1

Anti-Lysoganglioside Antibody Titer Protocol

[0112]The first assay is used to measure human serum IgG titers against lysoganglioside using the below described ELISA method. The antibodies are detected by coating microtiter plate wells with specific antigens, incubating the plates with serial dilutions of human sera, and washing away unbound antibodies. A secondary antibody conjugated to alkaline phosphatase is added to the plate and, after incubation, the excess conjugate is washed away. A color-developing substrate solution is then added. The amount of color developed is directly proportional to the amount of antibody in the sample. As always, when working with human fluids, biosafety practices must be followed.

[0113]The following materials were used:

MaterialDetailsLysoganglioside GM1from bovine brain (Sigma-Aldrich - G5660); store at −20° C.96-Well ELISA platesImmulon IV flat bottom plates (Thermo Scientific)Multichannel pipetFisherbrandPlastic wrapSingle channel pipettersGibsonDis...

example 2

Anti-Tubulin Antibody Titer Protocol

[0128]The second assay is used to measure human serum IgG titers against tubulin using the below described ELISA method. The antibodies are detected by coating microtiter plate wells with specific antigens, incubating the plates with serial dilutions of human sera, and washing away unbound antibodies. A secondary antibody conjugated to alkaline phosphatase is added to the plate and, after incubation, the excess conjugate is washed away. A color-developing substrate solution is then added. The amount of color developed is directly proportional to the amount of antibody in the sample. As always, when working with human fluids, biosafety practices must be followed.

[0129]The following materials were used:

MaterialDetailsTubulinfrom bovine brain (MP Biomedicals - 08771121); storelyophilized powder at 4° C., once reconstituted with includedPIPES buffer store at −80° C.96-Well ELISA platesImmulon IV flat bottom plates (Thermo Scientific)Multichannel pipet...

example 3

Anti-Dopamine D1 Receptor Antibody Titer Protocol

[0144]The third assay is used to measure human serum IgG titers against dopamine D1 receptors using the below described ELISA method. The antibodies are detected by coating microtiter plate wells with specific antigens, incubating the plates with serial dilutions of human sera, and washing away unbound antibodies. A secondary antibody conjugated to alkaline phosphatase is added to the plate and, after incubation, the excess conjugate is washed away. A color-developing substrate solution is then added. The amount of color developed is directly proportional to the amount of antibody in the sample. As always, when working with human fluids, biosafety practices must be followed.

[0145]The following materials were used:

MaterialDetailsDopamine D1 receptor400 μl frozen aliquot, membranes from cells (Membrane TargetSystems, Perkin Elmer 6110513400UA); at −80° C.96-Well ELISA platesImmulon IV flat bottom plates (Thermo Scientific)Plastic wrapMu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
widthaaaaaaaaaa
ODaaaaaaaaaa
total volumeaaaaaaaaaa
Login to View More

Abstract

The present invention provides a panel of at least five clinical analyses or tests (using serum samples) to determine the risk of pediatric acute-onset neuropsychiatric syndrome (PANS) and / or pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) in an individual. These include enzyme linked immunosorbent assays (ELISAs) to measure antibody titers against neuronal antigens present in the brain; the neuronal antigens include lysoganglioside, tubulin, dopamine receptor D1, dopamine receptor D2, serotonin receptor 5HT2A, and serotonin receptor 5HT2C. Antibody titers against at least four of these neuronal antigens are required in the present methods; preferably antibody tiers against all of these neuronal antigens are measured. A final assay is used to quantify calcium / calmodulin-dependent protein kinase activity using a neuronal cell line. The results of these analyses or tests are then combined using an algorithm to determine whether a PANS or PANDAS diagnosis is appropriate for the individual. Depending on the diagnosis, an appropriate treatment can be determined.

Description

RELATED APPLICATIONS[0001]This application claims the benefit and priority to and is a continuation of U.S. application Ser. No. 14 / 209,493, filed Mar. 13, 2014, which is based on, and claims the benefit of priority to, U.S. Provisional Application 61 / 787,919 filed on Mar. 15, 2013, which is hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention provides a convenient and accurate diagnostic method for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococci infection (PANDAS). The ability to reliably diagnose PANS and / or PANDAS using such a method allows treating clinicians to prescribe treatments in a more effective and timely manner than currently possible. Such ability to reliably diagnose PANS and PANDAS is expected to allow significant improvement in the outcomes of many patients with PANS and / or PANDAS.[0004]2. Description of the Related...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68G01N33/564
CPCG01N33/6854G01N2800/28G01N33/564G01N33/6896G01N33/56944G01N2333/315G01N2469/20G01N33/686G01N2333/726G01N2333/912G01N2405/10G01N2800/26G01N2800/30G01N2800/38
Inventor CUMMINGHAM, PHINA MADELEINESHIMASAKI, CRAIG DAVIDSWEDO, SUSAN E.
Owner THE BOARD OF RGT UNIV OF OKLAHOMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com